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Abstract: Fragile-X syndrome is a hereditary
dynamic mutation disorder, predominantly
caused by a large expansion of CGG
trinucleotide repeats in the FMR 1 gene
leading to methylation and down regulation
of transcription of the gene. For the
molecular diagnosis of the disease, the repeat
locus in FMR 1 gene is primarily detected by
Southern blotting with radioactively labeled
probes. Unusually GC rich composition of the
expanded region caused technical difficulties
during PCR based testing and therefore is not
performed by most diagnostic laboratories.
We established a Southern blot method and a
novel PCR protocol which enables the
amplification of normal, premutated and full
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Introduction
Fragile-X syndrome is an X-linked dominant disorder
with reduced penetrance in females and characterized by
moderate to severe mental retardation, large head, long
face, large ears, and large testicles (macroorchidism). It is
recognized as the most prevalent form of inherited
mental deficiency. The overall prevalence is estimated to
be about 1:4000 for males and 1:6000 for females (1).
It has been elucidated that the silencing of the FMR 1
gene, located at Xq 27.3, is responsible for the disease (2,
3). The FMR 1 gene was cloned and characterized in
1991 (4-8).
The gene contains unstable repeat sequences of
(CGG)n at 5’-untranslated region in exon 1. In a normal
population CGG repeat is polymorphic and varies in length
from 6-50 repeats (9). In phenotypically normal carriers
the expanded repeat numbers range from 50-200 and
become unstable (premutation). When unstable, the copy
number changes during transmission from parent to

mutated alleles. In both techniques bands are
visualized by digoxigenin labeled probe and
chemiluminescent detection. Although
diagnosis of fragile-X was possible by
cytogenetic analysis in our division, it was not
possible to diagnose premutation carriers or
mosaic fragile-X patients. This newly
established nonradioactive PCR and Southern
blot analysis will provide routine detection of
full fragile-X mutations and premutations in
our laboratory and therefore enable us to
offer accurate genetic counseling and
prenatal diagnosis.
Key Words: Fragile-X, molecular diagnosis,
nonradioactive labeling, polymerase chain
reaction.

child. This process is termed dynamic mutation. In most
fragile-X patients the CGG repeat is significantly increased
in length to more than 200 repeats (full mutation)
(5,7,9,10). The change from normal copy number to full
mutation is a multi step process proceeding through
premutation steps, rather than a single event
characteristic of classical mutation. In addition, an
upstream promoter region of the gene, CpG island, is
abnormally methylated in most affected individuals (4,6).
This finding led to the hypothesis that expansion to full
mutation size causes the hypermethylation of this
promoter region and thereby inactivates the FMR1 gene.
Amplification of CGG repeats and abnormal methylation
show a correlation with affected status.
Diagnosis of fragile-X syndrome has been available by
means of cytogenetic analysis for many years. However,
there have been some problems in identifying mosaic
males, premutations and some full mutation females
(11). For these reasons, alternative methods have been
pursued in many molecular laboratories during the past
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decade. The recently developed FMR protein antibody
test allows rapid detection in male patients using blood
smears and is found to be a suitable screening test for the
population of retarded males (12-13). Presently two
molecular methods are preferred for the detection of
patients and carriers of fragile-X syndrome (14-16). The
most widely used protocol is direct Southern blot
hybridization of genomic DNA digested with a pair of
restriction enzymes, one of which is methylation sensitive
(17). In this method, the extent of amplification and level
of methylation can be simultaneously detected. The other
protocol is the use of polymerase chain reaction (PCR) to
rapidly detect the size of the repeat expansion (18,19).
Compared with the well-established Southern blot
method, the PCR protocol contains major technical
difficulties in amplifying higher premutated and full
mutated alleles due to strong secondary structures of this
region.
We describe here the establishment of Southern blot
and PCR methods for the molecular analysis of fragile-X
syndrome in our laboratory. In both methods
nonradioactive DIG system was used for the detection
(20, 21). A novel PCR method based on the use of
Expand Long PCR system was designed to amplify
normal, premutated and full mutated alleles. This is the
first report in Turkey of nonradioactive molecular
diagnosis of fragile-X syndrome and detection of full
mutation males and females by a PCR based method.
Materials and Methods
Fragile-X Families
We analyzed 32 DNA samples isolated from the blood
samples of eight fragile-X affected families that had been
clinically and cytogenetically assessed in our clinic (22).
For the control of our molecular results, part of the DNA
samples were sent to the Center for Human Genetics in
Leuven, Belgium, for DNA analysis by Southern blot (17).
DNA Isolations
5 ml of peripheral blood collected in K3EDTA tubes
was used from each subject. DNA was isolated with a DNA
isolation kit (Boehringer Mannheim).
Genomic Southern Hybridization
Genomic DNA (5µg) was digested with both EcoR1
(50 U, Boehringer Mannheim) and methylation sensitive
enzyme EclX1 (isochimer of Eag1, 25U, Boehringer
Mannheim). Digestion products were separated on an
agarose gel (0.7 %) along with DIG-labeled molecular
weight marker (MW VII, Boehringer Mannheim) and
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transferred to a nylon membrane (positively charged)
following denaturation and neutralization procedures.
DNA was crosslinked to the membrane by UV light. Blot
was prehybridized for 4 hours, then hybridized with DIG
labeled pFxa1NHE probe (Oncor) in DIG Easy Hyb buffer
(Boehringer Mannheim) at 60 °C shaking in a
hybridization oven (Hybaid) for 16 hours. After stringent
washing of the membrane, the bands were detected
according to the procedures described in the DIG
Luminescent Detection kit (Boehringer Mannheim).
Incubation of CSPD was performed at 37 °C for 15 min,
and the membrane was exposed to X-ray film for 16-18
hours.
PCR Assay
Amplification of the CGG repeat region of normal,
premutated and full mutated alleles in the FMR1 gene
was carried out by PCR reaction with a total volume of
25 µl, containing 200 ng of genomic DNA, 300 nm of
each primer (23), 5 % of DMSO, 5 % of glycerol, Expand
Long PCR buffer 1 (Boehringer Mannheim), 350 µM of
each of dATP, dCTP, and dTTP, 350 µM of 7-deaza dGTP
and 1 U Expand Long Template PCR Kit Enzyme Mix
(Boehringer Mannheim). Denaturation was performed at
96 °C for 2 min. The samples were then subject to 10
cycles of amplification (96 °C 30 s; 54 °C 30 s; 68 °C for
8 min) in a thermocycler (MJ Research). The reaction was
stopped on ice, following the last denaturation for further
addition of an enzyme (1U), and continued for 30 more
cycles (96 °C 30 s; 52 °C 30 s; 68 °C for 8 min). The
reaction was finalized by keeping the reaction at 68 °C
for 12 min then 4 °C. The PCR products were run on 1.2
% agarose (molecular screening, Boehringer Mannheim)
gel.
Blotting
procedure,
hybridization
and
chemiluminescent detection were performed as
mentioned above for genomic southern hybridization.
The only difference was that the hybridization buffer
contained digoxigenin-labeled 5’-(CGG)5-3’ probe (5
pmol/ml) instead of the above mentioned Oncor probe.
X-ray exposure was approximately 1-2 hours.
For the indirect screening test, which enables the
amplification of normal alleles only, a similar PCR
protocol was used except 100 % 7-deaza dGTP was
replaced by 75 % 7-deaza dGTP, the elongation time was
reduced to 3 minutes, the reaction was not interrupted
for extra addition of an enzyme and bands were visvalized
by ethydium bromide staining.
Results
Overall, we tested 32 subjects of which 13 were
analyzed by both techniques. The total number of
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samples tested by the Southern blot method was 21 and
by the PCR method 24. Tested subjects versus status of
the individuals are outlined in Table 1. The results
obtained from Southern blot and PCR were in agreement
with the results provided by the Center for Human
Genetics in Leuven, Belgium.
Although our primary aim was to establish a
convenient PCR method for the molecular analysis of
fragile-X families, we also wanted to set up a Southern
blot method for comparison of our PCR results since the
latter is a common method used by most diagnostic
laboratories and possesses an advantage of providing
information regarding the methylation status of the
promoter region.
Genomic Southern Hybridization
The strategy used for Southern blot analysis is
illustrated in Figure 1. EcoR1 and methylation sensitive
enzyme EclX1 (isochimer of Eag1) digest of genomic DNA
gives the band pattern shown in Table 2. EcoR1/EclX1
double digest gave a normal band size of 2.8 kb for
normal males. In normal transmitting males the size of
these bands was increased to 3.4 kb. In affected males,
band size was increased above 5.8 kb due to the addition
of more than 200 repeats causing methylation of the CpG
islands. In premutation and full mutation carrier females
the band pattern was similar to males but there were
additional bands contributed by a second X chromosome.
In normal females two fragments were detected: 5.2 kb
(inactive X chromosome) and 2.8 kb (active X
chromosome) (17, 24). In mutational mosaic males or
females, the expected band sizes are variable reflecting
some cells with full mutation which are fully methylated
and some cells with premutation with no methylation
(15).
Typical results of normal and fragile-X subjects from
Southern blot analysis by DIG labeled pFxa1NHE probe

are illustrated in Figure 2. The premutation carrier
mother (lane 3) had two band patterns as expected
between 2.8-3.4 kb and 5.2-5.8 kb regions. Her
daughter (lane 1) was found to have full mutation
showing one normal allele at 2.8 kb and a full mutated
allele, not clearly visible in this photograph, at 7.5 kb,
indicated by the arrow. Her son (lane 2), had a full
mutated allele at 7.5 kb range. Normal male and normal
female band patterns were as expected (lanes 4 and 5
respectively). Normal transmitting male (lane 6) had band
sizes of 2.8 kb and 4.0 kb. The analysis result of this
patient complies with the mutational mosaic individuals
stated to contain some cells with the normal number of
repeat copies while some other cells with premutation or
full mutation copy numbers (15).
PCR
The amplification of the CGG locus of the FMR1 gene
is not possible by classical PCR conditions. Therefore, the
conditions that affect the amplification of CG rich regions
(denaturation temperatures, elongation times, DMSO and
glycerol concentrations, addition of 7-deaza dGTP) had to
be modified. In addition, annealing temperatures, enzyme
concentration, and primers also play an important role
for specific amplification of this region. In our study, we
tried 6 different primers in 9 different combinations
under various PCR conditions (23, 25, 26). One set of
forward and reverse primers were elected to provide the
specific amplification (23). Normal repeats were amplified
with 75 % 7- deaza dGTP and visualized by ethydium
bromide staining. The typical result of this study is shown
in Figure 3. Amplification bands of normal male were
seen while full mutation male (lane 6) was not visualized.
This method can be used as a simple test for indirect
screening to eliminate normal males from further
analysis. However, it may give false negative results for
mosaic males, therefore should not be preferred for
routine application.
Table 1.

Tested Subjects
Total 32
Status
Normal
(7)
Premutation
(15)
Full mutation
(10)

Only by Southern Blot

Only by PCR Test

Southern Blot + PCR Test

2

1

4

5

6

4

1

4

5

The outline of total type of
tests versus status of the
subjects.
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5.2 kb
pFax1NE
2.8 kb
EcoRI

EclX1

EcoRI

CpG

Figure 1.

(CGG)n

FMR 1

FMR 1 gene region with the area of size amplification, restriction sites with pFxa1NE probe. EcoR1 gives a normal band size of 5.2 kb.
DNA of normal male is unmethylated and gives a 2.8 kb band from EcoR1/EclX1 double digestion. In nontransmitting males the size of
these bands is increased by the length of the -CGG- repeats. In affected males, EclX1 does not cut methylated DNA then EcoR1/EclX1
digestion gives only an identical band to that of EcoR1 digestion alone (5.2 kb plus the size of the amplification). Mosaic males for
premutation and full mutation gives the combination of unmethylated and methylated patterns depending upon fragment size. In normal
females the promoter region is methylated on inactive X chromosome and therefore two fragments are detected: 5.2 kb from inactive X
and 2.8 kb from active X. In premutation and full mutation females, amplified bands are like those in males, but there are additional bands
contributed by the second X chromosomes.

Table 2.
Type of mutation
(CGG repeats)

Genomic Southern Hybridization
(kb)
MALE
FEMALE

PCR Test
(bp)

Normal
(6-50)

2.8

2.8 + 5.2

480-612

Premutation
(50-200)

2.8– 3.4

2.8; 2.8–3.4
5.2; 5.2–5.8

613 – 1062

Full Mutation
(> 200)

> 5.8

2.8
5.2; > 5.8

> 1062

Mosaic
(50-200 + > 200)

2.8; 2.8-3.4
> 5.8

2.8; 2.8-3.4
5.2; > 5.8

480-612
612-1062; > 1062

Reliable amplification of premutation and full
mutation alleles were successful only when a high
denaturation temperature (96 °C) and 100 % 7-deaza
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Size expected from genomic
Southern hybridization and
PCR test for normal,
premutation and affected
individuals.

dGTP are used with 5 % DMSO and 5 % glycerol. The
efficiency of the reaction was obtained by readdition of
the enzyme after the first 10 cycles of the PCR since high
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1

2

3

4

5

denaturation temperatures partially inactivate the
enzyme. PCR products were visualized by DIG detection
system following DIG labeled oligonucleotide probe
hybridization. The expected band pattern of PCR protocol
is listed in Table 2. According to our PCR protocol,
normal alleles of 6-50 repeats gave 480-612 bp,
premutation of 50-200 repeats gave 613-1062 bp and
full mutation of more than 200 repeats gave bands
bigger than 1062 bp. Depending on the mutational
variety of the cells, mosaics are expected to give bands at
normal size as well as premutation and full mutation
sizes. Typical results of the analysis of a fragile-X family
by PCR are illustrated in Figure 4. On the X-ray film, PCR
results of two fragile-X families are shown. Premutation
carrier mother (lane 4), had one amplification band for
normal allele of 537 bp correlated to 25 repeats and
another major amplification band at 741 bp correlated
with 93 repeats. Her full mutated son (lane 2) had a
smear above 1500 bp which correlated with more than
345 repeats; and her full mutated daughter (lane 3)
showed one normal allele size with 537 bp correlated to
25 repeats and smear above 1288 bp which correlated
with repeats above 274. The sister of this mother (lane
1) was also found to be a premutation carrier with
normal allele size of 562 bp correlating to 32 repeats and
other major band at 944 bp exhibited expanded allele size
of 159 repeats. The second family was representative for
two premutation carrier females, mother and daughter,
(lanes 5 and 6 respectively) with normal allele
amplifications around 524 bp correlated to 21 repeats

6

7100 bp
4800 bp
3500 bp
2700 bp

Figure 2.

Southern blot analysis with DIG labeled probe pFxaNE and
chemiluminescent detection of fragile-X family members.
Lane 1: full mutation carrier female, lane 2: full mutation
male, lane 3: premutation carrier female, lane 4 and 5:
normal male and normal female, respectively. Lane 6:
normal transmitting mosaic male. The sizes in bp are
shown on the left. Pedigree symbols are as follows: open
circle, normal female; open square, normal male; dot in
square, normal transmitting male; dot in circle, female
premutation carrier; striped circle, female with full
mutation; shaded square, full mutated male.

M

M

1

2

3

4

5

6

Figure 3.

The results of simple PCR
amplification with 75 % 7deaza dGTP protocol of normal
male (lanes 1-5) and full
mutation male (lane 6) subjects.
The bands are separated on 1 %
agarose gel and stained with
ethydium bromide. Amplified
normal alleles were visualized
while no amplification band was
observed with full mutation
males. M indicates lane the
marker.

normal allele

257

Establishment of a Nonradioactive Molecular Diagnosis of Fragile-X Syndrome

1

2

3

4

5

6

7

full-mutation

pre-mutation
normal

Figure 4.

Expand Long PCR assay and chemiluminescent detection of
normal, premutated and full mutated alleles in two
unrelated fragile-X families. Lanes 1, 4, 5 and 6:
premutation carrier female, lanes 2 and 7: full mutation
males, lanes 3: full mutation carrier female. The sizes in bp
are shown on the left. The size range of normal,
premutated and full mutated alleles are shown on the right.
Pedigree symbols are as follows: dot in circle, female
premutation carrier; striped circle, female with full
mutation; shaded square, full mutated male.

and expanded allele size at 754 bp with 97 repeats and
794 bp with 109 repeats, respectively. Her full mutated
son (lane 7) exhibited one major band at 1318 bp
corresponding to 285 repeats.
Discussion
Diagnosis of the fragile-X syndrome is generally
applied by cytogenetic and molecular techniques.
Although molecular diagnosis is rapidly replacing
cytogenetic diagnosis because of its lower cost and
greater reliability, cytogenetic analysis may still be needed
to confirm the clinical diagnosis of the index case by
excluding other chromosomal abnormalities in a newly
diagnosed fragile-X family.
The two molecular methods currently used for
detection of fragile-X mutations are Southern blot
hybridization and PCR analysis. The main advantage of
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Southern blot is its ability to discriminate methylation
sensitivity simultaneously with the expanded size of the
region. However, this accessory has now been overtaken
by new studies on PCR (27). The advantage of PCR is
that it is rapid, the materials are generally less expensive
and size resolution is more accurate. The simple PCR
protocol with 75 % 7-deaza dGTP and ethydium bromide
staining can separate normal males from fragile-X males
and therefore could be used as an indirect screening test
for nonspecific mental retardation cases. Since two alleles
are expected from females, this test is not suitable as an
screening test for females. In addition, this simple test
may give false negative results for normal transmitting
males and mosaic males, and therefore is not an
appropriate test for further application on clinically and
cytogenetically diagnosed fragile-X families.
Amplification of the CG rich regions is technically very
difficult due to the secondary structures of this region.
Modification of the critical parameters of the classical
PCR protocol, like replacing dGTP with 7-deaza dGTP,
adding DMSO and glycerol, using high denaturation
temperatures and adding fresh enzyme during the
reaction, help to provide better denaturation of the
region while keeping the enzyme active and stable for
amplification. In our established PCR method, alleles
carrying full mutation appear as a smear around a
condensed band, probably due to further denaturation
problems of the strong secondary structures of this
region. Sometimes, alleles carrying premutation appear
as a major band surrounded by minor bands. These bands
may either reflect true heterogenity of genomic DNA
isolated from peripheral blood or be produced due to
recombination artifact during PCR amplification (28).
When analyzing an identified fragile-X family, both
direct genomic hybridization and PCR analysis are
currently used for the diagnosis of fragile-X syndrome.
Our next aim is to establish a methylation sensitive PCR
method to overcome the need for Southern blot.
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